Author: Chinnici, Cinzia Maria; Russelli, Giovanna; Bulati, Matteo; Miceli, Vitale; Gallo, Alessia; Busà , Rosalia; Tinnirello, Rosaria; Conaldi, Pier Giulio; Iannolo, Gioacchin
Title: Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment Cord-id: 8m4sbh20 Document date: 2021_5_7
ID: 8m4sbh20
Snippet: Due to their immunomodulatory potential and release of trophic factors that promote healing, mesenchymal stromal cells (MSCs) are considered important players in tissue homeostasis and regeneration. MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage. Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome, including the extracellular vesicles, representing a promising approach in reg
Document: Due to their immunomodulatory potential and release of trophic factors that promote healing, mesenchymal stromal cells (MSCs) are considered important players in tissue homeostasis and regeneration. MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage. Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome, including the extracellular vesicles, representing a promising approach in regenerative medicine application to treat organ failure as a result of inflammation/fibrosis. The recent outbreak of respiratory syndrome coronavirus, caused by the newly identified agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has forced scientists worldwide to use all available instruments to fight the infection, including the inflammatory cascade caused by this pandemic disease. The use of MSCs is a valid approach to combat organ inflammation in different compartments. In addition to the lungs, which are considered the main inflammatory target for this virus, other organs are compromised by the infection. In particular, the liver is involved in the inflammatory response to SARS-CoV-2 infection, which causes organ failure, leading to death in coronavirus disease 2019 (COVID-19) patients. We herein summarize the current implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment, and emphasize the potential of MSC-based therapy in this clinical setting.
Search related documents:
Co phrase search for related documents- abdominal pain and acute inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and acute renal injury: 1, 2, 3, 4
- abdominal pain and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- abdominal pain and liver absence: 1, 2
- abdominal pain and liver biopsy: 1, 2, 3, 4
- abdominal pain and liver cell: 1
- abdominal pain and liver damage: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and liver direct damage: 1
- abdominal pain and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- abdominal pain and liver dysfunction: 1, 2, 3, 4
- abdominal pain and liver failure: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- abdominal pain and liver impairment: 1, 2, 3, 4
- abdominal pain and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- abdominal pain and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- abdominal pain and liver tissue: 1
- abdominal pain and liver transplantation: 1, 2, 3, 4, 5, 6, 7
- abdominal pain and lung damage: 1
- abdominal pain and macrophage inflammatory: 1
Co phrase search for related documents, hyperlinks ordered by date